☰

Artios Pharma

One data spine across discovery, trials and CDMOs

Industry
Biotechnology
Headquarters
Cambridge, United Kingdom
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Artios Pharma's published strategy and is not endorsed by, or produced in cooperation with, Artios Pharma. Company website

Strategic priorities

Artios is a clinical-stage DNA damage response (DDR) biotech developing alnodesertib, an ATR inhibitor with FDA Fast Track designation in ATM-negative metastatic colorectal cancer, and ART6043, a Polθ inhibitor in solid tumours. The Series D round in November 2025 raised $115 million from RA Capital, SV Health Investors and Janus Henderson, and is intended to carry alnodesertib through Phase 2 expansion toward registration-enabling data by 2027.

Manufacturing runs through a global CDMO network rather than in-house facilities, and discovery runs through the DcoDeR platform combining whole-genome sequencing, transcriptomics and high-content imaging. Joining those two data shapes — discovery genomics on one side, CDMO batch and clinical site data on the other — to the patient stratification work the pipeline depends on is the work the data spine has to do.

The near-term operational pressure sits in two places. First, the Babraham Research Campus labs in Cambridge need a GxP-aware digital lab platform as Phase 2 expansion brings more frequent regulatory interactions under the Fast Track programme. Second, the regulatory and ESG documentation load is rising: Green Impact Platinum status was renewed in July 2024, Fast Track brings heightened inspection readiness, and registration-enabling submissions are on the 2027 horizon.

The company is small relative to the work it has signed up for: a lean R&D organisation carrying registration-grade documentation, clinical supply and ESG reporting on fragmented toolchains. The clearest entry points are an ontology-based data model across discovery and clinical data, a paperless lab layer for GxP-aligned record keeping, and narrow AI agents for the document work that scales with sites and submissions.

Challenges we see

  • Operations Manufacturing

    Linking CDMO batch and clinical data into the discovery data spine

    Artios conducts manufacturing entirely through Contract Development and Manufacturing Organisations (CDMOs) for both alnodesertib and ART6043, with clinical operations spanning the UK and the US through a New York office. API and drug product release data therefore live in different systems than the DcoDeR discovery data and the Phase 2 trial data.

    Where the source data sits in separate systems at the sponsor, the CDMO and the clinical sites, patient-stratification work that needs to compare ATM mutation status against pharmacokinetic profile depends on a data layer that reconciles all three.

  • Digital Integration

    Capturing instrument data from heterogeneous lab equipment without manual transcription

    The Babraham Research Campus houses a mix of bioreactors, mass spectrometers and chromatography units feeding the DcoDeR platform. Industry benchmarks reported in life-science operations research put the share of researcher time spent on data collection at roughly 65 percent when instruments are not networked into a shared capture layer.

    When instrument output lands in spreadsheets and shared documents rather than in a structured lab record, the volume of manual handling before analysis scales with the number of runs, which constrains how many hypotheses the discovery platform can test in a quarter.

  • Compliance Regulatory

    Producing GxP-aware documentation at registration-grade frequency

    FDA Fast Track designation for alnodesertib is associated with more frequent regulatory interactions and inspection readiness, and the registration-enabling data target sits on the 2027 horizon. Discovery work also flows through experimental narratives in Excel and shared documents that are not GxP-aware.

    Where the same laboratory record is read by a researcher during discovery and by an inspector during a regulatory interaction, the record has to be trustworthy in both contexts at once, which makes audit trail and electronic signature decisions load-bearing from the start.

  • Operations Integration

    Reconciling global Phase 2 trial data with patient stratification logic

    Alnodesertib is being studied in ATM-negative metastatic colorectal cancer with expansion cohorts planned. Patient eligibility depends on confirming ATM-deficient status across trial sites that use different assays and reporting conventions, and the data reconciliation work currently runs through manual steps.

    When patient selection depends on reconciling genomics, assay results and clinical data across multiple sites, the reconciliation cycle rather than the laboratory cycle ends up on the critical path for cohort enrolment.

  • Sustainability Operations

    Maintaining ESG measurement as clinical operations scale

    Artios was awarded Green Impact Platinum in July 2024, based on a culture of sustainability embedded across the Babraham site. The current measurement of water and energy usage is manual, and clinical operations scaling through CDMOs and additional trial sites will increase the reporting surface area.

    Where environmental performance is currently captured by hand, keeping an externally audited Platinum rating while operational footprint grows means measurement has to move from periodic manual reporting to continuous instrumented capture.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unifying discovery, clinical and CDMO data on one ontology

    DcoDeR discovery data (whole-genome sequencing, transcriptomics, high-content imaging), CDMO batch and release data, and Phase 2 clinical data currently sit in separate systems with separate vocabularies. The patient-stratification work the pipeline depends on needs them together.

    An ontology-based data model that defines the entities both sides share — ATM mutation, assay, specimen, batch, lot, site, patient — once, then loads discovery output and clinical/CDMO data against it, lets the combined data set be queried once instead of reconciled per report.

    • Artios announces $115 million Series D financing, November 2025
    • Artios science: targeting DDR and DcoDeR platform description

  2. Replacing paper-based lab workflows with a GxP-aware ELN/LES

    Experimental narrative and result capture at the Babraham labs currently runs through Excel and shared documents, which are not GxP-aware and lack the audit trail a Phase 2 inspection-ready organisation needs.

    An Electronic Lab Notebook (ELN) and Laboratory Execution System (LES) layer that captures experimental narratives, instrument output and audit trail together lets the same record serve the researcher during discovery and the inspector during a regulatory interaction.

    • Artios Fast Track designation press release, ATM-negative mCRC
    • Artios ESG page: Green Impact Platinum, July 2024

  3. Bringing CDMO production data into a single operations view

    Artios relies entirely on external CDMOs for GMP-compliant API and drug product manufacturing. Each CDMO publishes batch and release data in its own format and on its own schedule, so the sponsor's view of supply chain health is reconstructed after the fact.

    Module Type Package (MTP)-aligned data streams and OPC UA (Open Platform Communications Unified Architecture) connectivity from CDMO sites into a central Process Orchestration Layer let the CMC team see batch progress and quality across partners in one view, with the data path defined contractually rather than reconstructed.

    • Artios official statement on manufacturing via CDMO partners
    • Artios Series D press release, November 2025

  4. Automating the document work that scales with sites and submissions

    Regulatory submissions, change-control documents, periodic reviews and ESG reporting all consume specialist time, and much of that time goes on assembling and checking documents rather than on the technical judgement inside them. The volume scales with sites, partners and jurisdictions.

    Narrow AI agents can draft documents from source records, check completeness against a template before review, and find every controlled document a standards change touches, with a named reviewer approving each output.

    • Artios Series D press release, November 2025
    • Artios ESG page: Green Impact Platinum, July 2024

  5. Designing a digital twin of the CDMO manufacturing process before scale-up

    Manufacturing scale-up to support registration-enabling trials runs through CDMOs that Artios does not directly control. Conditions such as pH, dissolved oxygen and temperature are sensitive to small changes, and Artios has limited visibility into how those conditions actually run at the partner.

    A process digital twin calibrated against historical CDMO batch data lets the CMC team explore parameter ranges virtually before committing to physical batches, and serves as the shared reference when discussing process changes with the partner.

    • Artios science: DcoDeR platform and pipeline
    • Artios manufacturing disclosure, official statements

What we'd propose

  • Enterprise AI

    Ontology-based data platform for DcoDeR and clinical reconciliation

    A data platform with an agreed ontology for the entities both sides share — ATM mutation, assay, specimen, batch, lot, site, patient — that loads DcoDeR discovery output and Phase 2 clinical and CDMO data against the same model, with validation at the boundary.

    • Shared DDR data ontology

      One agreed set of terms

      Define the entities and relationships the pipeline depends on — ATM mutation, transcriptomic profile, assay, specimen, drug exposure, response — so a query written once returns comparable answers across discovery and clinical data instead of two dialects of the same table.

    • Pipelines from instruments, CDMOs and clinical sites

      Loading both sides

      Build ingestion for Babraham instrument output, CDMO batch and release feeds, and Phase 2 trial site data, with schema validation at each boundary so bad records fail loudly rather than silently.

    • Analytics and retrieval on top of the model

      Questions answered without IT tickets

      Expose the model through dashboards and a retrieval layer so bioinformatics, clinical operations and CMC teams can ask questions of the combined data set without commissioning a new extract for each one.

    • Integration work is done once against a shared model rather than once per point-to-point interface.
    • Patient stratification work joins discovery and clinical data instead of being reconciled per analysis.
    • Future pipeline assets attach to the same model rather than triggering another migration.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    GxP-aware ELN and LES for the Babraham labs

    We replace Excel and shared-document experimental capture with a validated ELN and LES layer that captures experimental narratives, instrument output and audit trail together, so the same record serves the researcher and the inspector.

    • Electronic lab notebook integration

      One record for experimental narrative

      Deploy a validated ELN that captures experimental narratives, protocols and results with a complete audit trail, replacing fragmented Excel and shared-document workflows.

    • Instrument-to-system data capture

      Direct instrument output

      Connect bioreactors, mass spectrometers and chromatography units so results are captured with instrument identity, method version and timestamp attached, rather than read off a screen and re-typed.

    • GxP compliance engine

      Validated before each step

      Implement training-status and instrument-calibration checks in the workflow so a regulated operation cannot proceed unless its prerequisites are recorded as current, producing inspection-ready evidence by default.

    • The same record supports the researcher during discovery and the inspector during a regulatory interaction.
    • Manual transcription steps drop out of the lab cycle, freeing researcher time for analysis.
    • GxP evidence is produced as the work happens, rather than assembled for review.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    MTP and OPC UA connectivity into CDMO production floors

    We define the data path between CDMO partners and Artios's central operations view using MTP-aligned module interfaces and OPC UA connectivity, so batch and release data arrive as data rather than as monthly reports.

    • MTP-aligned CDMO module specification

      Standard data contract with partners

      Write the Module Type Package (MTP) interface description into CDMO partner requirements, so each partner's production module exposes a documented data contract that Artios's Process Orchestration Layer can consume without per-site customisation.

    • Secure OPC UA connectivity

      Encrypted shop-floor to sponsor

      Establish OPC UA connectivity from CDMO production floors into Artios's central systems, with the protocol's authentication and encryption used to protect proprietary synthesis methods while still enabling real-time batch visibility.

    • Unified production dashboard

      One view across partners

      Build a centralised monitoring interface that aggregates batch progress and quality metrics across CDMO sites, so the CMC team sees the supply chain as one system rather than as a stack of partner reports.

    • Supply chain status is read from the source rather than reconstructed from partner reports.
    • Manufacturing visibility scales across CDMO partners without per-site integration projects.
    • Process change conversations with partners rest on a shared data reference.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Process digital twin for CDMO manufacturing scale-up

    We build a calibrated digital twin of the alnodesertib and ART6043 manufacturing processes that lets the CMC team explore parameter ranges and process changes virtually, using historical CDMO batch data as the reference.

    • Bioprocess simulation engine

      Validated process model

      Deploy a simulation environment calibrated against historical CDMO batch data, modelling the small-molecule synthesis steps and the environmental parameters (pH, temperature, dissolved oxygen) that drive product quality.

    • Parameter exploration and sensitivity

      Find good ranges before running them

      Run parameter sweeps and sensitivity studies in the model, so the team identifies stable operating ranges and ranks the parameters that matter most before discussing process changes with the CDMO.

    • Shared reference with the CDMO

      One model, two organisations

      Establish the digital twin as the shared reference for process-change discussions, so the sponsor and the CDMO talk about the same predicted behaviour rather than about different recollections of past runs.

    • Process risk is reduced by testing parameter ranges in the model before committing to physical batches.
    • Process-change discussions with the CDMO rest on a shared quantitative reference.
    • Calibration history is preserved across batches, so model accuracy improves with each campaign.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for regulatory, change-control and ESG documentation

    Narrow, reviewable agents that take the repetitive part of the document work that scales with sites, partners and submissions: drafting regulatory and change-control documents from source records, checking completeness before review, and finding every controlled document a standards change touches. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of regulatory submissions, change-control documents, periodic reviews and ESG reports directly from the underlying system records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and Artios's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change-impact search across the controlled document set

      Which documents a change touches

      When a standard, partner agreement or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Regulatory, change-control and ESG document cycles move faster because documents arrive complete.
    • The scope of a standards change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Artios Pharma's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 35 → 82
DcoDeR discovery data and clinical/CDMO data sit in separate systems, with patient-stratification work depending on manual reconciliation. The Series D capital provides headroom to address this ahead of the 2027 data target.
Lab digitalization 42 → 78
The Babraham facilities are state-of-the-art, but experimental workflows run through Excel and shared documents. Fast Track inspection readiness means the record needs to be trustworthy in both research and regulatory contexts.
CDMO manufacturing visibility 28 → 72
Manufacturing is entirely external, with no real-time data path into the sponsor. The technical standards (MTP, OPC UA) for closing that gap are available; the contractual adoption with partners is the work.
Regulatory documentation 52 → 85
Fast Track designation brings more frequent regulatory interactions, and the 2027 registration-enabling data target is on the horizon. Documentation volume scales with sites, partners and submissions, not with headcount.
Process automation 38 → 75
Advanced scientific capability coexists with manual data capture and reconciliation. Reducing manual handling is the prerequisite for the discovery platform to test more hypotheses per quarter.
ESG measurement 32 → 68
Green Impact Platinum is maintained by manual reporting today. Keeping the rating as clinical operations scale means measurement has to move from periodic manual reporting to continuous instrumented capture.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Artios Pharma, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].